Scarica l'app Stockscreener
5.21
4.23%
-0.23
Pre-mercato:
5.05
-0.16
-3.07%
Karyopharm Therapeutics Inc Borsa (KPTI) Ultime notizie
Karyopharm Therapeutics jumps 18%, raises $30M privately - MSN
KPTI Stock Down on Mixed Phase III Myelofibrosis Combo Study Data - TradingView
KPTI stock slumps pre-market even as Karyopharm’s myelofibrosis treatment meets primary endpoint — retail doubtful about FDA approval - MSN
KPTI: Baird Lowers Price Target, Maintains Outperform Rating | K - GuruFocus
Karyopharm Therapeutics (NASDAQ:KPTI) Price Target Lowered to $15.00 at Robert W. Baird - MarketBeat
HC Wainwright Lowers Karyopharm Therapeutics (NASDAQ:KPTI) Price Target to $8.00 - MarketBeat
H.C. Wainwright cuts Karyopharm stock price target on trial results By Investing.com - Investing.com Canada
HC Wainwright & Co. Lowers Price Target on Karyopharm Therapeuti - GuruFocus
Karyopharm raises $30M in private placement with RA Capital By Investing.com - Investing.com Australia
Karyopharm Therapeutics Falls As Pivotal Trial Hits Spleen Goal But Misses Symptom Mark - Sahm
Karyopharm Therapeutics Inc. (KPTI) Discusses Top Line Results From Phase III SENTRY Trial in MyelofibrosisSlideshow (NASDAQ:KPTI) 2026-03-25 - Seeking Alpha
Karyopharm myeloma drug yields mixed data in myelofibrosis trial - BioPharma Dive
Karyopharm’s myelofibrosis trial meets one of two primary goals By Investing.com - Investing.com India
KPTI Shares Fall Following Varied Results from Phase III Myelofibrosis Combination Study - Bitget
Leerink cuts Karyopharm stock price target on mixed trial data By Investing.com - Investing.com Canada
Why Is Karyopharm Therapeutics Stock Trading Lower Today?Karyopharm Therapeutics (NASDAQ:KPTI) - Benzinga
Karyopharm to seek label expansion for Xpovio in myelofibrosis after late-stage trial win - MSN
Karyopharm’s Phase 3 SENTRY Trial Shows Significant Spleen Reduction and Promising Overall Survival in Myelofibrosis with Selinexor Plus Ruxolitinib 1 - Minichart
Karyopharm phase III Sentry entry bucks rux in MF; to FDA next - BioWorld MedTech
Karyopharm, looking to jump-start Xpovio, reports mixed results in myelofibrosis - Fierce Pharma
Karyopharm research and financing developments - The Pharma Letter
Karyopharm shares rise 10% after mixed Phase 3 SENTRY trial results - MSN
KPTI Stock Faces Uncertainty Amid Financial Challenges - StocksToTrade
Karyopharm Therapeutics SENTRY Trial Hits Spleen Endpoint, Shows Early Survival Signal in Myelofibrosis - MarketBeat
RBC Capital maintains Outperform on Karyopharm stock after trial data By Investing.com - Investing.com Canada
RBC Capital maintains Outperform on Karyopharm stock after trial data - Investing.com
Karyopharm Therapeutics (KPTI) Stock Plunges 12.71% on $30M Financing Announcement - Blockonomi
Karyopharm (KPTI) Announces Positive Phase 3 Trial Results for S - GuruFocus
Karyopharm Therapeutics Inc. (KPTI) Stock: Drops 12.71% After $30M Private Placement Deal - CoinCentral
Karyopharm Shares Jump 10% Following Mixed Phase 3 Trial Outcomes on Myelofibrosis Treatment - StockInvest.us
Why Did KPTI Stock Tank 13% In Pre-Market Today? - Stocktwits
Karyopharm Therapeutics (KPTI) Secures $30M in Private Placement, Stock Soars - GuruFocus
KPTI: Selinexor plus ruxolitinib nearly doubled spleen response and improved survival in myelofibrosis - TradingView
Karyopharm Therapeutics Secures $30M Private Placement with RA Capital Management - citybiz
Karyopharm Announces Financing and Positive SENTRY Trial Results - TipRanks
Karyopharm (KPTI) Shares Surge After Positive Selinexor Trial Re - GuruFocus
Karyopharm Therapeutics Raises ~$30 Million in RA Capital Private Placement, $44 Million Warrant Upside - TradingView
SENTRY myelofibrosis data and $30M private placement reshape Karyopharm (NASDAQ: KPTI) - Stock Titan
Karyopharm posts trial win for Xpovio in myelofibrosis (KPTI) - Seeking Alpha
Karyopharm (KPTI) Announces $30M Private Placement Deal - GuruFocus
Karyopharm stock gains 10% on mixed Phase 3 trial data - Investing.com UK
Karyopharm stock gains 10% on mixed Phase 3 trial data By Investing.com - Investing.com South Africa
Karyopharm raises $30M in private placement with RA Capital - Investing.com
Karyopharm Therapeutics' blood cancer drug meets one of two main goals in study - TradingView
Karyopharm Therapeutics announces topline results from Phase 3 SENTRY trial in myelofibrosis - Traders Union
Karyopharm's Phase 3 SENTRY Trial in Myelofibrosis Met First Co-Primary Endpoint, Demonstrating Statistically Significant Improvement in Spleen Volume Reduction - Karyopharm
Karyopharm Announces $30 Million Private Placement with RA Capital - PR Newswire
New myelofibrosis drug combo shrank spleens in half of patients - Stock Titan
How The Selinexor Story Is Reframing Karyopharm Therapeutics (KPTI) And Its Growth Expectations - Yahoo Finance
Karyopharm Therapeutics Inc.: Fundamental Analysis and Financial Ratings | | US48576U2050 - marketscreener.com
Profit Recap: How sensitive is Karyopharm Therapeutics Inc to inflationShort Setup & Long-Term Safe Investment Plans - baoquankhu1.vn
Myelofibrosis Pipeline 2026: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Galecto Biotech, Lynk Pharma, Samus Therapeutics, Taiga Biotech, Bristol-Mye - StreetInsider
KPTI SEC FilingsKaryopharm Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Stock Traders Purchase Large Volume of Call Options on Karyopharm Therapeutics (NASDAQ:KPTI) - MarketBeat
HC Wainwright & Co. Downgrades Karyopharm Therapeutics (KPTI) - MSN
Karyopharm Therapeutics (KPTI) Price Target Decreased by 10.98% to 15.98 - MSN
Karyopharm signals $130M–$150M revenue target for 2026 with pivotal myelofibrosis data readout ahead - MSN
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Short Interest Update - MarketBeat
Rodman & Renshaw initiates coverage of Karyopharm Therapeutics (KPTI) with buy recommendation - MSN
1.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):